EditCo Bio: Uncovering Novel Cancer Therapeutic Targets: Accelerating Discovery Through Streamlined CRISPR Cell Engineering

This session brings together leading-edge research in molecular oncology, gene editing, and computational biology to deepen our understanding of cancer mechanisms and therapeutic strategies. Dr. Simon Lebaron, Research Scientist at the Centre de Biologie Intégrative in Toulouse, will discuss his lab’s research, recently published in Nature Communications, on the role of SURF2 in nucleolar stress, elucidating its function as a potential therapeutic target in cancer treatment, supported by CRISPR-mediated knockout models. Dr. Daniel Miller, Principal Scientist at London-based biotech Evariste, will explore AI-driven methodologies in synthetic lethality, demonstrating how computational pipelines enhance the identification of novel cancer vulnerabilities. Lastly, Dr. Amalia Soenens will outline EditCo’s latest innovations in high-throughput cell engineering and their impact on accelerating cancer research. This session offers a critical platform for oncology researchers, molecular biologists, and translational scientists to engage with cutting-edge developments in cancer biology and precision medicine.